Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC) (MEN_BOC)
|ClinicalTrials.gov Identifier: NCT01457937|
Recruitment Status : Unknown
Verified September 2012 by Prof. Facchinetti Fabio, University of Modena and Reggio Emilia.
Recruitment status was: Recruiting
First Posted : October 24, 2011
Last Update Posted : October 2, 2012
University of Modena and Reggio Emilia
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Prof. Facchinetti Fabio, University of Modena and Reggio Emilia
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||June 2014|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. World J Gastroenterol. 2014 Nov 28;20(44):16726-33. doi: 10.3748/wjg.v20.i44.16726.